# Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Study · id `cardio:ct-nct01438814` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01438814](<https://clinicaltrials.gov/study/NCT01438814>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01438814

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 689 participants.

## Technical summary

Registry record NCT01438814. Randomized; double masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2014-06-03.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 689 participants (enrolled count; ClinicalTrials.gov record NCT01438814, source copy `cardio:ctgov-nct01438814-2014-11-25`, retrieved 2026-10-26)
- Start date: 2011-11 (registry gives no type) (ClinicalTrials.gov record NCT01438814, source copy `cardio:ctgov-nct01438814-2014-11-25`, retrieved 2026-10-26)
- Primary completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01438814, source copy `cardio:ctgov-nct01438814-2014-11-25`, retrieved 2026-10-26)
- Completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01438814, source copy `cardio:ctgov-nct01438814-2014-11-25`, retrieved 2026-10-26)
- Results first posted: 2014-06-03 (ClinicalTrials.gov record NCT01438814, source copy `cardio:ctgov-nct01438814-2014-11-25`, retrieved 2026-10-26)
- Countries: Bangladesh; Belgium; Canada; China; Germany; Guatemala; Hong Kong SAR China; India; Lebanon; Mexico; Peru; Philippines; Spain; Taiwan (ClinicalTrials.gov record NCT01438814, source copy `cardio:ctgov-nct01438814-2014-11-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01438814-2014-11-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): metformin placebo
- Intervention (Drug): linagliptin placebo
- Intervention (Drug): metformin
- Intervention (Drug): metformin
- Intervention (Drug): linagliptin
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial (`cardio:pubmed-25805187`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 247750097bd4481c2d7ab731cec4ab4d0be3fa08dd69b3ce11b4bb2c8170bbef
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
